Casey Tansey Acquires 35,572 Shares of Mobia Medical (NASDAQ:MOBI) Stock

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey bought 35,572 shares of the business’s stock in a transaction dated Thursday, August 13th. The stock was acquired at an average cost of $11.51 per share, for a total transaction of $409,433.72. Following the completion of the acquisition, the director directly owned 268,904 shares in the company, valued at approximately $3,095,085.04. This trade represents a 15.25% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Mobia Medical Price Performance

Shares of NASDAQ:MOBI opened at $11.74 on Tuesday. Mobia Medical, Inc. has a 1-year low of $10.19 and a 1-year high of $15.29. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. The firm has a market cap of $390.84 million and a PE ratio of -0.61. The stock’s fifty day simple moving average is $12.42.

Mobia Medical (NASDAQ:MOBI) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million for the quarter. The firm’s revenue for the quarter was up 102.4% on a year-over-year basis. Sell-side analysts expect that Mobia Medical, Inc. will post -2.76 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on MOBI shares. Wolfe Research initiated coverage on Mobia Medical in a research note on Tuesday, June 2nd. They set an “outperform” rating for the company. Weiss Ratings assumed coverage on Mobia Medical in a research note on Wednesday, August 12th. They issued a “sell (e-)” rating on the stock. Wall Street Zen raised Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Bank of America assumed coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Zacks Research upgraded Mobia Medical to a “hold” rating in a research note on Wednesday, June 3rd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.